The two companies will collaborate on the development of targeted NK cell and macrophage cells derived from induced pluripotent stem cells (iPSC), cementing a relationship that has already seen ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

研究结果表明，TGF-β信号阻断是NK细胞有效对抗肝细胞和其他表达高水平TGF-β的恶性肿瘤的必要条件。 这项研究证明了使用 IPSC 来源细胞替代大泡性 ...

The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function ...

As an important constituent of the innate immune system against cancer, phenotypic and functional deviations of NK cells have been demonstrated in HCC patients who also exhibit perturbation of the ...

The trial, dubbed CARAMEL, will mark the first evaluation of an allogeneic iPSC-derived CD19-directed NK cell therapy in autoimmune disorders. The investigator-initiated trial, sponsored by ...

五、针对下游应用优化关键PIVs 拟胚体（EB）的大小和密度（每毫升EB数）是iPSC聚集体分化为自然杀伤（NK）免疫细胞的关键工艺输入变量（PIVs）。虽然目前尚未确定从iPSC EBs生成NK细胞的最佳EB大小和密度，但这些PIVs可以通过调整生物反应器的搅拌速率（流体 ...